Albany, NY -- (SBWire) -- 07/22/2019 --Rosacea Market Insights, Epidemiology and Market Forecast-2028

1. Around 1 in 10 people in the world are affected by rosacea.
2. Rosacea total prevalent population in the 7 major markets was assessed to be 47,634,256 in 2017.
3. Rosacea total diagnosed prevalent population in the 7 major markets was evaluated to be 16,417,070 in 2017.

DelveInsight launched a new report on Rosacea Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Rosacea market report covers a descriptive overview and comprehensive insight of the Rosacea epidemiology and Rosacea market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Rosacea market report provides insights on the current and emerging therapies.
3. Rosacea market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Rosacea market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Rosacea market.

Request for sample pages

"Rosacea market size in seven major markets was USD 502.6 million in 2017 and will increase by 2028."

Expected launch of potential therapies may increase Rosacea market size in the coming years, assisted by an increase in Rosacea diagnosed prevalent population. The current therapeutic landscape of Rosacea can be divided into four major categories based on the route of administration and the approved usage for the condition. These are: Topical retinoids, Topical antibiotics, Oral tetracycline class antibiotics (TCAs) and Oral retinoids. Among the four class therapies (topical retinoids, topical antibiotics, oral tetracycline class antibiotics and oral retinoids), topical antibiotics is the most prescribed therapies, that led to highest Rosacea market size among other classes.
The United States account for the largest Rosacea market size in comparison to EU5 countries and Japan. Among the EU5 countries, Germany had the highest market size with USD 76.7 million in 2017, while Italy had the lowest Rosacea market size with USD 19.6 million in 2017.
Global Rosacea treatment market is segmented by treatment type, prescription drugs, and OTC products. OTC products are majorly driven by the patient's past experiences and satisfaction level; however, the prescription market is majorly lead by dermatologist and physicians with respect to the disease severity and line of therapy.

The marketed drugs still contribute a major share to Rosacea total market size. However, effectiveness of these therapies depend on the subtype as well as the severity of the disease. Due to these unmet need, many companies are developing the drugs for Rosacea treatment like:-
1. FMX103
2. VERED
3. Omiganan
4. ACU-D1
5. HY01
6. BPX-04
7. DFD-04 and DFD-29
8. and DMT210
and many others

Companies involved are:-
1. Foamix Pharmaceuticals
2. Sol-Gel
3. Cutanea Life Sciences
4. Accuitis
5. Hovione Scientia Limited
6. BioPharmX
7. Dermata Therapeutics
8. Promius Pharma
and many others

Table of contents

1. Key Insights
2. Rosacea Market Overview at a Glance
3. Rosacea Disease Background and Overview
4. Rosacea Epidemiology and Patient Population
5. Rosacea Total Prevalent Patient Population 7MM
6. Rosacea Total Diagnosed Prevalent Patient Population 7MM
7. Country Wise Rosacea Epidemiology
7.2. EU5 Countries
7.2.1. Assumptions and Rationale
7.3. Germany
7.4. France
7.5. Italy
7.6. Spain
7.7. United Kingdom
7.8. Japan
8. Rosacea Treatment Algorithm, Current Treatment, and Medical Practices
9. Rosacea Unmet Needs
10. Rosacea Marketed Drugs
10.1. Rhofade: Allergan
10.2. Oracea: Galderma Laboratories (Nestle Skin Health)
10.3. Mirvaso: Galderma Laboratories (Nestle Skin Health)
10.4. Finacea: Bayer
10.5. Soolantra: Galderma Laboratories, Inc. (Nestle Skin Health)
10.6. Metrogel: Galderma Laboratories (Nestle Skin Health)
11. Rosacea Key Cross Competition
12. Rosacea Emerging Drugs
12.1. FMX103: Foamix Pharmaceuticals
12.2. Epsolay: Sol-Gel 138
12.3. Omiganan: Cutanea Life Sciences
12.4. BPX-04: BioPharmX, Inc.
12.5. ACU-D1: Accuitis, Inc.
12.6. HY01 (Minocycline): Hovione Scientia Limited
12.7. DFD-04: Dr. Reddy's Laboratories
12.8. DFD-29: Dr. Reddy's Laboratories
12.9. DMT210: Dermata Therapeutics
13. Rosacea 7 Major Market Analysis
14. The United States Market Outlook
14.1. United States Market Size
15. EU-5 Countries: Market Outlook
15.1. Germany
15.2. France
15.3. Italy
15.4. Spain
15.5. United Kingdom
16. Japan: Market Outlook
17. Market Drivers
18. Market Barriers
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight